- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03437135
Screening and Characterization of Hearing Disorders in Diabetic Persons (DeCaTAuDiab)
Screening and Characterization of Hearing Disorders in Diabetic Persons.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes is now the most common chronic disease since it affects western populations such as France almost 6% of the population. This disease is particularly costly for social protection systems, not only for the cost of daily care but also by the occurrence of Chronic complications that are leading to major co-morbidities. Thus, diabetes is a major cardiovascular risk factor. Diabetes also leads to micro-angiopathic complications: Diabetic retinopathy eventually ends up in evolved forms to the first cause of young subject blindness in developed countries. Nephropathy is one of the first causes of terminal renal failure leading to extra renal treatment.
Diabetic neuropathy seems to be the most common and the most common of the specific complications of diabetes. It can of course touch the lower limbs, most often training a symmetrical and distal motor polyneuritis, responsible for the term of Neuro arthropathy of Charcot. The vegetative nervous system can also be achieved with cardiovascular, gastrointestinal, genitourinary, neuro-vascular, metabolic and pupil consequences. The injuries of the cranial nerves are also possible and are most frequently characterized by facial paralysis or motor eye nerves.
The association between hearing disorders and diabetes has always aroused controversy on the part of contradictory literature data. Are hearing disorders an underestimated complication of diabetes? A recent meta-analysis of 2013, examined the scientific literature between 1950 and 2011 and of the 3158 citations, only 13 articles were selected (with more than 20 000 participants). This study found that hearing disorders in diabetic patients were 2.1 times more prevalent than in non-diabetic paired subjects. In addition, the age/aging factor is associated with the prevalence of hearing impairment and diabetes. However, it also appears that the link between diabetes and hearing disorder is more pronounced among young people than the elderly.
Nevertheless, it is regrettable that in the majority of the "diabetes-hearing disorders" studies were not exhaustive from the point of view of the documentation of the alteration of the hearing function. Indeed, the indices of impairment of the hearing are essentially based on a review of the audiograms. No more relevant objective test, allowing to evaluate more precisely the different functional compartments of the inner ear, has been achieved. Indeed, it would be wise to elucidate which (s) are the targets (s) of the diabetes. Classical hearing impairment mainly affects cochlear sensory cells and more specifically external hair cells. However, it is possible to envisage that the alteration of the micro-vascularization of the vascular Streak (ischemic disorders), a selective expectation of the nerve fibers (hearing neuropathy), the metabolic disturbances at the mitochondrial level, Oxidative stress with free radical production, advanced glycation products (AGE, advanced glycation end-products).
Objectives:
- The primary objective is the assessment of the prevalence of hearing impairment (with or without clinical manifestation) in a population of type 1 and type 2 diabetic persons treated and followed during a hospitalization or consultation in the Department of Endocrinology-Diabetology of the CHU de Clermont-Ferrand.
- The second objectives are:
Identify the proportion of patients with a peripheral explanation for their hearing impairment (involvement of the outer ciliated cells, 'classic deafness) Identify the proportion of patients who have a neural explanation for their hearing impairment (hearing-type neuropathy) And categorize types of hearing impairment by types of diabetes, its balance, age, absence or absence of complication, age of patient, sex of patient, noise exposure in a professional manner or as a part of recreation, taking ototoxic drugs, smoking.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- CHU clermont-ferrand
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- type 1 or type 2 diabetic patients
Exclusion Criteria:
- history of otological surgical act
- presence of neurological or psychiatric disorders that may impair the quality of explorations
- presence of a obstructive wax stopper or au foreign body found in the simple otoscopy (or impossibility of this extraction).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Witness patients
Healthy Volunteers
|
This is a questionnaire of the hearing quality presenting eleven questions.
This is allows to determine the quality of the hearing status of the patients.
It is enough to answer the various questions "yes" or "no".
|
|
Type 1 diabetic patients
patients with type 1 diabetes
|
This is a questionnaire of the hearing quality presenting eleven questions.
This is allows to determine the quality of the hearing status of the patients.
It is enough to answer the various questions "yes" or "no".
|
|
Type 2 diabetic patients
patients with type 2 diabetes
|
This is a questionnaire of the hearing quality presenting eleven questions.
This is allows to determine the quality of the hearing status of the patients.
It is enough to answer the various questions "yes" or "no".
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
presence or not of an ear wax cap
Time Frame: At day 1 (during the inclusion and screening consultation)
|
A single ostoscopie is performed using a portable otoscope and single-use Speculum to verify the absence of any wax cap.
|
At day 1 (during the inclusion and screening consultation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mobility of the eardrum-ossicular
Time Frame: At day 1 (during the inclusion and screening consultation)
|
From a tympanometry probe with a single-use mouthpiece, the mobility of the eardrum is studied and therefore the functional state of the middle ear.
|
At day 1 (during the inclusion and screening consultation)
|
|
Study of Stapedius reflex
Time Frame: At day 1 (during the inclusion and screening consultation)
|
From a tympanometry probe with a single-use mouthpiece, the study of Stapedius reflex allows to evaluate the functionality of a reflex neurological loop of the brainstem.
The stapedium reflex rating is "present " or "absent "
|
At day 1 (during the inclusion and screening consultation)
|
|
Study of acoustic ear emissions
Time Frame: At day 1 (during the inclusion and screening consultation)
|
A measuring probe is carefully inserted into the external ear canal and an analysis of the overall responses of the cochlea is carried out following the application of an acoustic stimulation.
The ear emission rating is "present " or "absent
|
At day 1 (during the inclusion and screening consultation)
|
|
the auditory threshold
Time Frame: At day 1 (during the inclusion and screening consultation)
|
A tonal audiogram for 6 frequencies from 250 to 8000 will be achieved to determine of auditory threshold
|
At day 1 (during the inclusion and screening consultation)
|
|
the functionality of external ciliated cells (ECC)
Time Frame: At day 2 (during the exploration consultation)
|
this is a non-invasive, simple, fast and objective assay for exploring the functionality of external ciliated cells (ECC).
This test is similar test in some aspects to the test of acoustic ear emissions, but allows to have an analysis of cochlear answers (and more specifically ECC) not global but between 1000 hertz and 8000 hertz
|
At day 2 (during the exploration consultation)
|
|
Early auditory evoked potentials (or eAEP)
Time Frame: At day 2 (during the exploration consultation)
|
Electrodes are positioned at specific points at the level of the scalp (according to the system 10/20, at the level of the vertex and in frontal-median Fp).
|
At day 2 (during the exploration consultation)
|
|
frequency selectivity of the patient
Time Frame: At day 2 (during the exploration consultation)
|
the objective of this test is to measure the selectivity in frequency for three frequencies (1000, 2000 and 4000hertz).
|
At day 2 (during the exploration consultation)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-371
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
DiappyMedSanoiaRecruitingDiabetes Type 1 | Pancreatogenous Diabetes | Diabetes Type 2 on InsulinFrance
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
Clinical Trials on Glasgow Hearing Status Inventory questionnaire
-
Chania General Hospital "St. George"University of ThessalyNot yet recruitingDepression | Anxiety | Cognitive Function 1, Social | Satisfaction, Consumer | Amplification | Hearing Aid | Listening Effort
-
Oticon MedicalCompletedHearing LossUnited States, Spain, Canada
-
Oticon MedicalCompletedHearing LossSpain, Denmark, United Kingdom
-
University of NottinghamNational Institute for Health Research, United Kingdom; International Stem...CompletedQuality of Life | Cancer | Hearing Loss, Sensorineural | Tinnitus, Subjective | Late EffectUnited Kingdom
-
Benno Rehberg-KlugCompleted
-
Sohag UniversityCompletedSocial Anxiety DisorderEgypt
-
Oticon MedicalCompletedHearing LossDenmark, United Kingdom, Netherlands, Sweden
-
Bursa Yüksek İhtisas Education and Research HospitalCompletedDepression | Fatigue | Fibromyalgia | Anxiety | Sjogren's Syndrome | Pain SyndromeTurkey
-
Riphah International UniversityCompletedCABG | Post-cardiac SurgeryPakistan
-
Bezmialem Vakif UniversityRecruiting